July 30, 2026
National and international nominations are being sought for the 2027 Harrington Prize for Innovation in Medicine, which honors a physician-scientist who has moved science forward with achievements notable for innovation, creativity and the potential for clinical application. The Harrington Prize, which carries a $20,000...
Continue Reading
June 30, 2026
Cleveland.com article authored by Julie Washington and advance local express, published on June 30, 2026 CLEVELAND, Ohio — A shortage of nitric oxide—a gas the body produces naturally—may be tied to faster disease progression in Alzheimer’s patients, according to researchers at University Hospitals and Case Western... Continue Reading
June 05, 2026
Researchers at the Harrington Discovery Institute at University Hospitals have identified a new class of potential drug targets for cancers that stop responding to existing treatments. Continue Reading
May 20, 2026
WKYC TV Interview Continue Reading
February 28, 2026
Harrington Scholar Dr. Diana Farmer Published in The Lancet Continue Reading
February 28, 2026
I feel emotional thinking about how medical science has evolved to offer new hope of saving lives. Continue Reading
February 26, 2026
The Oxford-Harrington Rare Disease Centre (OHC) highlights its commitment to driving progress for rare disease—impacting the lives of families like Cynthia Schulz and her daughter Noni who spent decades living answers or effective treatments for CASK Continue Reading
February 06, 2026
Harrington Discovery Institute at University Hospitals is supporting the development of a new drug called Zalunfiban that helped thousands of heart attack patients avoid complications in clinical trials. Continue Reading
January 29, 2026
Oxford-Harrington Rare Disease Centre operates a transatlantic model that embeds industry expertise directly into academic rare disease programs. $250 Million Committed to Advance 40 Therapies into Clinical Trials by 2034 Continue Reading
December 23, 2025
A conversation with Matthew P. Anderson, MD, Ph.D., co-director, Oxford-Harrington Rare Disease Centre, featured in Drug Discovery Online Continue Reading
December 16, 2025
Despite the central role of p53 suppression in cancer pathogenesis, the promise of therapeutic p53 reactivation remains unrealized, with targeted and combination chemotherapies limited by efficacy, toxicity, and delivery. Continue Reading